Company news
Sellas Life Sciences Group, Inc. (NASDAQ:SLS) news
Sellas Life Sciences Group, Inc. news releases on 6ix. Latest, May 14, 2024: SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides…
Press releases — page 2
SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level
April 30, 2024
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study
April 28, 2024
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
March 25, 2024
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
March 18, 2024
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
March 14, 2024
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
March 7, 2024
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
February 29, 2024
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
February 28, 2024
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
February 5, 2024
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
January 24, 2024
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
January 8, 2024
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
January 3, 2024
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
January 2, 2024
SELLAS Life Sciences Announces Proposed Public Offering
January 2, 2024
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
December 26, 2023
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
December 20, 2023
SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
December 13, 2023
SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
December 12, 2023
SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
December 3, 2023
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
November 28, 2023
SELLAS Life Sciences Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls (CMC) Biologics License Application (BLA) Filing Strategy for Galinpepimut-S (GPS)
November 12, 2023
SELLAS Provides Business Update and Reports Third Quarter 2023 Financial Results
November 8, 2023
SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society...
November 5, 2023
SELLAS Life Sciences Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 30, 2023
SELLAS Life Sciences Receives Fast Track Designation from FDA for SLS009 for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas
October 29, 2023
SELLAS Life Sciences to Present Final Data from Phase 1/2 Study of Galinpepimut-S in Combination with Keytruda® (pembrolizumab) in Patients with WT1+ Platinum-Resistant Advanced Ovarian Cancer at the International Gynecologic Cancer Society 2023 Annua...
October 16, 2023
SELLAS Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia
October 15, 2023
SELLAS Life Sciences Provides Update on Phase 3 REGAL Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia
October 11, 2023
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas
October 10, 2023
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
October 9, 2023
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
September 20, 2023
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
September 17, 2023
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
August 21, 2023
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
August 9, 2023
SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
June 27, 2023
SELLAS Announces First Patient Dosed in Phase 2a Clinical Trial of GFH009 in Acute Myeloid Leukemia
June 21, 2023
SELLAS Life Sciences Announces Abstract Accepted for Presentation at International Gynecologic Cancer Society Annual Meeting
June 14, 2023
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
June 12, 2023
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
May 24, 2023
SELLAS Life Sciences to Host Virtual Expert Panel Discussion on GFH009 in Acute Myeloid Leukemia
May 15, 2023
SELLAS Life Sciences Provides Business Update and Reports First Quarter 2023 Financial Results
May 10, 2023
SELLAS Announces Positive Topline Data from GFH009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study
May 3, 2023
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
April 25, 2023
SELLAS Life Sciences Successfully Completes Phase I Trial Dose Escalation of Novel, Highly Selective CDK9 Inhibitor GFH009 in Acute Myeloid Leukemia
April 19, 2023
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
April 17, 2023
SELLAS Life Sciences Reports Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
SELLAS Announces Publication of Positive GPS Clinical Data in Ovarian Cancer in Peer Reviewed Journal
March 6, 2023
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
February 23, 2023